CV scores $185M royalty deal on Lexiscan

Just a week after gaining regulatory approval for Lexiscan (regadenoson), an injection that increases arterial blood flow during heart tests, CV Therapeutics sold off a 50 percent interest in its North American royalties to TPG-Axon Capital for $175 million and a $10 million milestone payment. Astellas Pharma, which is marketing the drug, is paying CV a $12 million milestone payment on the approval. A European application for Lexiscan is expected later this year. Palo Alto, CA-based CV is scheduled to get an FDA decision on Ranexa for a subset of diabetes patients in July.

TPG-Axon was spun out of Texas Pacific Group and is led by Dinakar Singh, the former head of Goldman Sachs' Principal Strategies Department. Shares of CV Therapeutics shot up 19 percent in after-hours trading on the news of the deal.

- check out the release
- read the story in the San Francisco Business Times
-
read the report in Wall Street 24/7

Related Articles:
CV, Astellas gain Leixscan approval. Lexiscan report
CV Therapeutics gains $7 million on NDA filing. CV report
CV, Astellas present positive Phase III results. CV, Astellas report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.